Pulmonary hypertension affects ∼10% of adult patients with sickle cell disease (SCD), particularly those with the homozygous genotype. An increase in pulmonary artery systolic pressure, estimated noninvasively by echocardiography, helps identify SCD patients at risk for pulmonary hypertension, but definitive diagnosis requires right-heart catheterization. About half of SCD-related pulmonary hyp...

Pulmonary arterial hypertension is an obstructive pulmonary vasculopathy and the RV considered a major determinant of survival in patients with precapillary hypertension. The transition from adaptive to maladaptive phenotype remains poorly understood clinically unpredictable. Several mechanisms having been suggested right heart disease but causes cardiac remodeling remain unknown require furthe...

Copyright © 2011 Massachusetts Medical Society. Chronic thromboembolic pulmonary hypertension is defined as mean pulmonary-artery pressure greater than 25 mm Hg that persists 6 months after pulmonary embolism is diagnosed. The 2008 World Symposium on Pulmonary Hypertension1 emphasized the importance of chronic thromboembolic pulmonary hypertension, which occurs in 2 to 4% of patients after acut...

BACKGROUND Limited data are available describing paediatric pulmonary arterial hypertension. AIMS To characterize the epidemiology, management and impact on quality of life and outcome of paediatric pulmonary arterial hypertension, excluding persistent pulmonary hypertension of the newborn and pulmonary arterial hypertension caused by congenital heart disease. METHODS In this multicentre st...

Pulmonary hypertension is a devastating and refractory disease and there is no cure for this disease. Recently, microRNAs and mesenchymal stem cells emerged as novel methods to treat pulmonary hypertension. More than 20 kinds of microRNAs may participate in the process of pulmonary hypertension. It seems microRNAs or mesenchymal stem cells can ameliorate some symptoms of pulmonary hypertension ...

Antisynthetase syndrome is characterised by the association of interstitial lung disease and myositis with different anti-tRNA-synthetase antibodies. The occurrence, aetiology and prognosis of pulmonary hypertension have not yet been evaluated. Among 203 consecutive patients, transthoracic echocardiogram and right heart catheterisation results were retrospectively analysed in the light of clini...

In their paper on combined preand post-capillary pulmonary hypertension, Assad et al. say that ‘‘the resistance-compliance (RC) time has emerged as a measure of pulmonary vascular physiology that integrates the mean and pulsatile afterload of the right ventricle.’’ They discuss reports in the literature of changes in RC time in a variety of conditions. The findings in their study show that ‘‘th...

Pulmonary arterial hypertension (PAH) is a progressive disease with high morbidity and mortality rates. Research has shown that PAH has a prevalence rate of 10-79% in thalassemia major patients. This cross-sectional study was carried out in 2014 to determine the prevalence and risk factors of PAH in all thalassemia major patients of over 18 years of age in Ilam, Iran. A cardiologist measured sy...